Dr. Bourgouin is a graduate MD from the University of Montreal and holds a M.Sc. in pharmacology from the same university. He followed a post-graduate course in clinical pharmacology and drug development at the University of Rochester (New-York, U.S.). After 10 years spent in general practice and consulting, Dr. Bourgouin joined the pharmaceutical industry where he held various prominent positions ranging from Director Clinical Research to Vice-President Scientific Affairs. Dr Bourgouin worked for a number of pharmaceutical companies such as Sandoz, Rhône-Poulence Rorer, Hoechst Marion Roussel and Aventis Pharma. His latest position was executive Vice-President and Chief Medical Officer of Wex Pharmaceuticals, a B.C. based biopharmaceutical company. Dr. Bourgouin is also an associate professor of the Pharmacology Department of the University of Montreal.
Dr Silvy Lachance received her M.D. degree in 1987 from the University of Sherbrooke where she completed an internship and residency training in Internal Medicine followed by a Fellowship in Hematology and Oncology at Montreal University and a Fellowship in Stem Cell Transplantation in Paris at Henri-Mondor University. In 1994, she completed a DEA in immunology at Pasteur Institute.
In 1995, she joined the Department of Medicine at the CUSE, University of Sherbrooke, and established its first Stem-cell Transplant Program and Unit while in 1997 she became Assistant Professor at McGill University and joined the Hematology and Oncology Division of The Montreal General Hospital as a transplant physician. Her dedication to teaching was recognized by the Douglas G. Kinnear Award in 2003 and by the very special best teacher awards from the hematology Fellows. She became an Associate Professor of Medicine at McGill University in 2005.
Dr. Lachance was the chair of the Continuing Medical Education Committee of the Quebec Association of Hematologists and Oncologists from 1999 to 2001 during which period the Association was accredited for the first time for its CME activities. She is currently the elected treasurer of the executive committee of the Hematologist and Oncologist Association. She was from 2002 and until 2006 the chair of the jury for the hematology specialty exam board of the CMQ (Collège des Médecins du Québec) and contributed to the standardization of the specialty exam, establishing criteria and guidelines in evaluation modalities.
Since June 2006 she joined the Stem Cell Transplant team of Maisonneuve-Rosemont Hospital and became the director of the Fellowship Program and Associate Professor of Medicine at Montreal University. Since 2008, she is the director of the stem cell transplant program of HMR.
Eric J Bow MD is Professor of Medicine and Medical Microbiology at the University of Manitoba, Winnipeg. He graduated from the University of Calgary, and trained in General Internal Medicine, Haematology and Oncology at McMaster University, Clinical Microbiology at the University of Toronto, and in Infectious Diseases at the University of Manitoba.
Dr. Bow currently holds positions as Medical Director, Clinical and Academic Services and Infection Control Services, CancerCare Manitoba; and Attending Physician in the Sections of Infectious Diseases and Haematology/Oncology, Department of Internal Medicine, University of Manitoba. He is also an Attending Physician in the Manitoba Blood and Marrow Transplant (MBMT) Programme.
From June 2009 to November 2012, Dr. Bow held the position of Medical Director, Oncology Programme, Winnipeg Regional Health Authority. From 1997 to June 2009, he held the positions of Head of the Section of Haematology/Oncology, University of Manitoba, Health Sciences Centre, and St. Boniface General Hospital; and Head, Department of Medical Oncology and Haematology, CancerCare Manitoba; and the position of Director and Chief of Services, GD6 Oncology Unit, Health Sciences Centre, Oncology Program, Winnipeg Regional Health Authority from 1990 to June 2009.
Dr. Bow’s research interests have focused upon the prevention and management of bacterial and fungal infections in neutropaenic cancer patients and cytotoxic therapy-induced intestinal epithelial damage in the pathogenesis of these infections. He is currently a member of several Clinical Practice Guidelines panels, including the Infectious Diseases Society of America, American Society of Clinical Oncology, the Centers for Disease Control and Prevention, and the Association for Medical Microbiology and Infectious Diseases Canada; a member of the Steering Committee for the International Mycoses Study Group; a member of the Multinational Association for Supportive Care in Cancer, Mucositis Study Group; and is a member of Council for the International Immunocompromised Host Society.
Dr. Lazaryan's clinical and research expertise is in the field of adult hematologic malignancies and blood and marrow stem cell transplantation. Dr. Lazaryan completed residency training in Internal Medicine followed by fellowship training in Hematology-Oncology at the Cleveland Clinic Foundation in Cleveland, Ohio, USA. He joined the faculty at the University of Minnesota in 2012. Dr. Lazaryan received his medical degree from Yerevan State Medical University in 1997 and a Master of Public Health Degree from the State University of New York at Albany in 2001 followed by a Doctorate Degree in Public Health at the University of Alabama at Birmingham in 2008. Dr. Lazaryan has authored multiple peer-reviewed publications and extensively presented his work at scientific meetings and conferences.
Prof. Dr. Nicole Blijlevens is an MD, PhD in internal medicine (subspecialty Hematology) and head of the department of hematology Radboud University Medical Centre (Radboudumc) in Nijmegen. Her research focus in general is on personalized supportive care to prevent and/or reduce side effects of cancer therapy for hematological diseases, especially infections in the stem cell transplant setting. Research topics are the development and validation of novel tools to predict the onset, course and severity of mucosal barrier injury (MBI) and infectious complications, to further investigate and develop new drugs for preventing or modulating MBI and transplant-related inflammation as to reduce the burden of ill-health, and unravel the role of microorganisms and intestinal innate immunity in initiating Graft-versus-Host-Disease.
She has been involved in several clinical trials and co-chaired several European studies in transplant patients on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). She is author of several international guidelines in the field of supportive care and published >90 peer-reviewed articles and invited chapters of several textbooks relating to MBI and gained her PhD in ‘Mucosal barrier injury and stem cell transplant recipients’ in 2005. She is a member of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer, the American Society of Hematology, the European Hematology Association and the European Society of Clinical Microbiology and infectious Diseases. She is member of the Working Party on Qualty of Cancer Care of the Dutch Cancer Society, secretary of Dutch Society of Hematology (NVvH), treasurer of the Dutch Foundation of Hemato-oncolgy in Adults (HOVON). She chairs the Supportive Care Working Party of HOVON, the Critical Support Working Party of HOVON and also chairs the Commission Evaluation of Effects and Costs of a National Program of efficiency in health care. Furthmore she is reviewer for several international journals, lectures to medical students and participates in postgraduate teaching of nurses and (para-)medics.
Dr M. Shetzline received his M.D. and Ph.D. from The Ohio State University, Columbus, Ohio in Physiology and Medicine. Dr. Shetzline had a successful career within academia serving as Gastroenterology Program Director and Assistant Professor of Medicine at Duke University Medical Center in the US. He performed basic research and fellowship training in hormone signaling with a focus on G-protein coupled receptor regulation and holds patents related to the use of receptor signalling technology in disease profiling. Mike is American Board of Internal Medicine certified in Internal Medicine and Gastroenterology. After 10 years in academic medicine as a clinician, researcher, and teacher at DUMC, Mike joined Novartis being responsible for gastroenterology clinical development programs as well as Global Phase IV studies. In 2006, he moved to the position as Executive Director and later VP at Novartis headquarters in Basel, Switzerland, where he spent 5 years and broadened his area of responsibility to include respiratory, cardiovascular, and metabolic diseases as well as translational medicine. Dr. Shetzline has been involved in successful approved drug development programs in the US and globally. In 2010, he relocated to Novartis in the US as VP and Global Program Head in Integrated Hospital Care, which also includes immunology and orphan diseases. After 10 years at Novartis, Mike joined Ferring Pharmaceuticals in 2012 as VP and Global Head of Gastroenterology, he has published over 40 full papers and book chapters and acted as a reviewer for a range of medical journals.
Florence Rozen is the Senior Scientific Advisor with Fonds de solidarité FTQ, a development capital organization based in Quebec. She obtained her Ph.D. in Biochemistry at McGill University in the laboratory of Dr. Nahum Sonenberg in 1989. Having done research in the fields of oncology and endocrinology at Merck Frosst and several McGill-affiliated hospitals and research institutions, she left the research world in 1999 to join MedTech Partners, a Quebec-based technology development company focused on early-stage investments in the medical and life sciences. In her role at the Fonds, a position she has held since 2009, she conducts scientific due diligence, technological assessment of potential investment opportunities and monitoring of scientific milestones of the Fonds Life Science portfolio companies.
Prior to joining CTI LSF as a Principal in 2006, Dr. Tilley was Senior VP at Drug Royalty Corporation, a Bay Street private equity firm doing investments in biopharmaceuticals. At DRC, she managed the due diligence and analysis group and participated in closing 12 transactions totaling over $200 M in invested capital.
Before DRC, Dr. Tilley ran and managed a research laboratory, holding faculty positions at the NYU School of Medicine and Public Health Research Institute, New York, and on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the National Institutes of Health Small Business Innovation Research (SBIR) program for 10 years.
Dr. Tilley holds a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine and an MBA from the University of Toronto. In addition, she is a member of the CFA Society Toronto, CFA Institute, CVCA, Canadian Women in Private Equity and BIOTECanada Emerging Companies Advisory Board.
Currently, Dr. Tilley is a Board Director for Xagenic and Zymeworks, investments that she led for CTI LSF; recently, she has enjoyed her first championed investment ‘exit’ via the Medicago acquisition by Mitsubishi Tanabe.